Autres langues Scholar Rock Holding Corporation

Actions

SRRK

US80706P1030

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/06/2026			Varia. 5j.	Varia. 1 janv.
54,76 ^USD	+1,80%		+15,70%	+24,31%

11/06	Médicaments anti-obésité : les laboratoires se bousculent sur un marché lucratif en pleine ébullition	RE
09/06	Transcript : Scholar Rock Holding Corporation Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 10:00 AM

Autres langues

22/06	Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD
12/06	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/06	Weight-loss drug developers line up to tap lucrative market as competition heats up
09/06	Weight-loss drug developers line up to tap lucrative market as competition heats up
26/05	Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
20/05	Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
15/05	Scholar Rock reports new employee inducement grants under Nasdaq Listing Rule 5635(c)(4)
15/05	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/05	Scholar Rock Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Scholar Rock Q1 Loss Widens
07/05	Earnings Flash (SRRK) Scholar Rock Posts Q1 Net Loss $0.83 a Share, vs. FactSet Est of $0.80 Loss
07/05	Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
29/04	Scholar Rock to Present at the BofA Securities 2026 Health Care Conference
21/04	Scholar Rock Holding Insider Sold Shares Worth $1,517,723, According to a Recent SEC Filing
20/04	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/04	Scholar Rock reports new employee inducement grants under Nasdaq Listing Rule 5635(c)(4)
17/04	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/04	Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026
31/03	Scholar Rock Resubmits Biologics License Application For Apitegromab For Treatment Of Children And Adults With Spinal Muscular Atrophy
31/03	Scholar Rock Resubmits Biologics License Application for Apitegromab to US FDA
31/03	Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
13/03	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/03	Scholar Rock Holding Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
03/03	Scholar Rock FY income from operations USD -384.645 million
03/03	Scholar Rock Q4 Net Loss Widens